GRAIL Faces Investor Class Action Over Disclosures on Cancer Trial
Law firm Hagens Berman is investigating claims that GRAIL, Inc. misled investors regarding its NHS-Galleri cancer screening trial. Investors who suffered substantial losses are encouraged to participate in the class action.
San Francisco – National shareholder rights firm Hagens Berman is investigating allegations against GRAIL, Inc. in a pending class action lawsuit. The suit claims the company violated U.S. securities laws by providing misleading information to investors about the clinical design and efficacy of its landmark NHS-Galleri cancer screening trial.
Hagens Berman is encouraging GRAIL investors who sustained significant losses to come forward. The class action covers the period from May 13, 2025, to February 19, 2026. The deadline for potential lead plaintiffs to file is August 4, 2026.
The lawsuit alleges that GRAIL repeatedly asserted the NHS-Galleri trial was designed to demonstrate a statistically significant reduction in late-stage cancer diagnoses within a three-year follow-up period. The complaint contends the company concealed internal data suggesting the timeframe was inadequate and selectively presented results while withholding crucial data indicating a lower probability of success.
On February 19, 2026, GRAIL announced that the NHS-Galleri trial failed to meet its primary endpoint. The company admitted that a longer follow-up period "probably should have been allowed." This disclosure caused GRAIL's stock price to drop by approximately 50.55%, erasing over $2.2 billion in market capitalization.
The investigation by Hagens Berman focuses on the timeline of when GRAIL and its management were aware that the required follow-up period for the trial exceeded the three years initially disclosed. Investors who purchased GRAIL stock during the specified class period and experienced financial losses may be eligible to serve as lead plaintiff in the litigation.